Vitae Pharmaceuticals (VTAE) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Vitae Pharmaceuticals Reports Second Quarter 2015 Operating and Financial Results
August 4, 2015 4:10 PM EDTMultiple potential milestones in 2H 2015
Conference call scheduled for 4:30 p.m. EDT today
FORT WASHINGTON, Pa., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio generated by its proprietary structure-based drug discovery platform, reported today its operating and financial results for the second quarter ended June 30, 2015.
"During the second quarter of 2015, we initiated a Phase 1 study of VTP-43742, our first-in-class RORt candidate for the treatment of autoimmune disorders. Initiation of this study was a... More
Vitae Pharmaceuticals Reports Second Quarter 2015 Operating and Financial Results
August 4, 2015 4:10 PM EDTMultiple potential milestones in 2H 2015
Conference call scheduled for 4:30 p.m. EDT today
FORT WASHINGTON, Pa., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio generated by its proprietary structure-based drug discovery platform, reported today its operating and financial results for the second quarter ended June 30, 2015.
"During the second quarter of 2015, we initiated a Phase 1 study of VTP-43742, our first-in-class RORt candidate for the treatment of autoimmune disorders. Initiation of this study was a... More
